The present study aimed to examine the impact of a 3-bp indel (rs57408770) polymorphism within the pre-microRNA (miR)-3131 polymorphism on prostate cancer (PCa) risk in a sample of an Iranian population. In total, 340 subjects, including 177 patients with PCa and 170 patients with benign prostatic hyperplasia, were enrolled in the present case-control study. A mismatch polymerase chain reaction-restriction fragment length polymorphism method was designed for genotyping the 3-bp indel (rs57408770) polymorphism. The present findings demonstrated that the indel variant significantly increased the risk of PCa in codominant [odds ratio (OR)=2.23, 95% confidence interval (CI)=1.13–4.37; P=0.021, insertion (ins)/ins vs. deletion (del)/del] and recessive (OR=2.33, 95% CI=1.25–4.36; P=0.009, ins/ins vs. del/del + del/ins). In conclusion, to the best of our knowledge, the present findings for the first time proposed that a 3-bp indel variant of miR-3131 may be a risk factor for susceptibility to PCa in a sample of an Iranian population. Further studies with different ethnicities and larger sample sizes are required to validate the present findings.
Prostate cancer (PCa), the second most common malignancy in men, is the fifth leading cause of cancer-related mortality among men globally (1). The incidence rate of PCa in Iran is lower than that in the rest of the world (2–4). Despite the high prevalence of PCa, little is known about the mechanisms underlying the development and progression of PCa. It has been proposed that genomic and environmental factors contribute to the development and progression of PCa (5–8). Twin studies have indicated that 42% of the variation in PCa risk may be attributed to genetics (9). Single nucleotide polymorphisms (SNPs), the most common type of genetic variation in the human genome, have been demonstrated to be associated with the risk of developing PCa (10–12).
MicroRNA (miR) are small, non-coding, endogenous, single-stranded RNA molecules that are ~22 nucleotides in length (13,14). They regulate gene expression by directing sequence-specific degradation or inhibiting translation of target mRNA (13,14). Mounting evidence has suggested that mutation or SNPs in miR genes may affect target-binding activity, expression, or processes of mature miR, thus affecting the expression of their target genes (15,16). Polymorphisms in mature and/or pre-miR sequences may affect miR biogenesis and be associated with the development of various types of cancer (17–21). Small insertions and deletion (indels) polymorphisms are one of the most common genetic alterations in the human genome that influence human traits and diseases (22,23). There is limited information regarding the association between pre-miR-3131 polymorphisms and cancer risk. Recently, Wang et al (20) investigated the impact of a 3-bp indel polymorphism (rs57408770) in pre-miR-3131 on hepatocellular carcinoma (HCC) and observed that the insertion (ins) allele significantly increased the risk of HCC in a Chinese population. To the best of our knowledge, for the first time, the present study aimed to determine the impact of a 3-bp indel polymorphism (rs57408770) within pre-miR-3131 on PCa susceptibility in a sample of an Iranian population.
Patients and methodsPatients
The present case-control study involved 177 patients with PCa (mean age, 61.45±6.78 years) and 177 individuals with benign prostatic hyperplasia (BPH) as controls (mean age, 62.43±7.68 years) admitted to hospital between February 2014 and March 2015. All cases and controls were elected from the Department of Urology, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences (Tehran, Iran). The study design and enrolment procedure were described previously (17,18,24). The project was approved by the local Ethics Committee of Zahedan University of Medical Sciences (Zahedan, Iran) and written informed consent was taken from all participants. Peripheral blood samples were collected in tubes containing EDTA and genomic DNA was extracted using the salting out method, as described previously (25).
Genotyping
Mismatch polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methods for genotyping were designed. Mismatched C was introduced into the forward primers of rs57408770 at −2 bp from the polymorphic site to create an AluI (New England BioLabs, Inc., Ipswich, MA, USA) restriction site. The forward and reverse primers were 5′-CTGTGCAGCTGACTCTGAGAAGACG-3′ and 5′-TATTGGCTCCTAGGAAGGCTGAGT-3′, respectively.
PCR was performed using commercially available prime Taq Premix (GeNet Bio, Nonsan, Korea), according to the manufacturer's instructions. Each 0.20 ml PCR reaction tube contained 1 µl genomic DNA (100 ng/ml), 1 µl each primer (10 µM), 7 µl 2X master mix and the appropriate amount of double-distilled H2O. Amplification was performed with an initial denaturation at 95°C for 6 min, followed by 30 cycles of 30 sec at 95°C, 30 sec at 65°C and 72°C for 30 sec, with a final extension step of 72°C for 5 min. For genotyping, 10 µl PCR product was digested by AluI and the digested products were separated by 2.5% agarose gel electrophoresis. The deletion (del) allele produced a 188-bp fragment, while the ins allele produced 171- and 20-bp fragments (Fig. 1).
Statistical analysis
Statistical analysis was conducted using SPSS v. 22 software (IBM Corp., Armonk, NY, USA). Data were analyzed by independent samples t-tests and χ2 tests. Unconditional logistic regression analysis was used to examine the association between the rs57408770 variant and PCa risk. P<0.05 was considered to indicate a statistically significant difference.
ResultsPatient characteristics
The present study consisted of 177 patients with PCa (mean age, 61.45±6.78 years) and 177 individuals with BPH (mean age, 62.43±7.68 years). No significant difference was observed between the age of the two groups (P=0.212; data not shown).
3-bp indel (rs57408770) polymorphism and risk of PCa
The genotypes and allele frequencies of the 3-bp indel (rs57408770) polymorphism within pre-miR-3131 in patients with PCa and control subjects are demonstrated in Table I. The findings revealed that the indel variant was significantly associated with increased risk of PCa in codominant [odds ratio (OR)=2.23, 95% confidence interval (CI)=1.13–4.37; P=0.021, ins/ins vs. reference del/del) and recessive (OR=2.33, 95% CI=1.25–4.36; P=0.009, ins/ins vs. reference del/del + del/ins). The ins allele was not significantly associated with the risk of PCa (OR=1.33, 95% CI=0.98–1.81; P=0.083).
Association between 3-bp indel polymorphism of pre-miR-3131 and clinicopathological characteristics
The association between the 3-bp indel polymorphism of pre-miR-3131 and clinicopathological characteristics, including age, stage, prostate specific antigen levels, Gleason score (18), perineural invasion and surgical margin, are demonstrated in Table II. The findings revealed that the 3-bp indel polymorphism of pre-miR-3131 was only significantly associated with perineural invasion (P=0.015). No significant association was observed between the variant and other clinicopathological characteristics in patients with PCa. The Hardy-Weinberg equilibrium (HWE) was calculated and the results indicated that the genotype distribution in cases and controls was consistent with HWE (χ2=2.41, P=0.121 and χ2=1.97, P=0.161, respectively; data not shown).
Discussion
Recent expression profiling studies in PCa suggest that miR may serve as potential biomarkers for PCa risk and disease progression (26–30). Growing evidence has indicated that mutation or polymorphisms in miR genes could affect target-binding activity, expression or processes of mature miR, consequently affecting the expression of their target genes (15,16). Polymorphisms in miR have been demonstrated to be associated with the development of PCa (17,18,31,32). In present study, it was hypothesized that the 3-bp indel polymorphism of pre-miR-3131 may be associated with the development of PCa. The present results indicated that the ins/ins genotype of the pre-miR-313 variant significantly increased the risk of PCa. To the best of our knowledge, there has only been one report regarding the impact of a 3-bp indel polymorphism of pre-miR-3131 on cancer risk (20). Wang et al (20) demonstrated that the insertion allele of a 3-bp indel polymorphism of pre-miR-3131 was significantly associated with an increased risk for HCC. Furthermore, their findings revealed that the 3-bp indel polymorphism could affect the expression level of miR-3131 by influencing the binding of splicing factor SRp20 with pre-miR-3131 (20). Hsa-miR-3131 is located on chromosome 2 in intron 2 of the Indian hedgehog gene and the 3-bp indel variant (rs57408770) is located in the 3′ end of miR-3131 (20). A study by Shen et al (33) demonstrated that the miR-3131 expression level was upregulated by 92-fold in HepG2 cells treated with Ganoderma lucidum polysaccharide, proposing that miR-3131 may be involved in the proliferation and differentiation of HCC cells.
Polymorphisms in miR genes, including pri-miR (17,34,35), pre-miR (36) and mature miR, may affect the processing of miR as well as the regulatory function on their target genes, and consequently may be implicated in the development and prognosis of various types of cancer (37–39). In conclusion, to the best of our knowledge, the present study provided evidence for the first time that the 3-bp indel polymorphism of pre-miR-3131 significantly increased the risk of developing PCa in a sample of an Iranian population. Therefore, the pre-miR-3131 3-bp indel variant may be a potential biomarker for prostate cancer. Further studies with different ethnicities and larger sample sizes are required to certify the present findings.
Acknowledgements
The present study was supported by a grant from Zahedan University of Medical Sciences (Zahedan, Iran; grant no. 7832).
ReferencesSiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin65529201510.3322/caac.2125425559415FarahmandMKhademolhosseiniFMehrabaniDTrend of prostate cancer in Fars Province, Southern Iran, 2001-2007J Res Med Sci15295297201021526101TalaiezadehATabeshHSattariAEbrahimiSCancer incidence in southwest of iran: First report from khuzestan population-based cancer registry, 2002–2009Asian Pac J Cancer Prev1475177522201310.7314/APJCP.2013.14.12.751724460327BaadePDYouldenDRCrambSMDunnJGardinerRAEpidemiology of prostate cancer in the Asia-Pacific regionProstate Int14758201310.12954/PI.1201424223402NtaisCPolycarpouATsatsoulisAMolecular epidemiology of prostate cancer: Androgens and polymorphisms in androgen-related genesEur J Endocrinol149469477200310.1530/eje.0.149046914640986ChokkalingamAPStanczykFZReichardtJKHsingAWMolecular epidemiology of prostate cancer: Hormone-related genetic lociFront Biosci1234363460200710.2741/232517485312ZhouXWeiLJiaoGGaoWYingMWangNWangYLiuCThe association between the APE1 Asp148Glu polymorphism and prostate cancer susceptibility: A meta-analysis based on case-control studiesMol Genet Genomics290281288201510.1007/s00438-014-0916-325234162BrattOHereditary prostate cancer: Clinical aspectsJ Urol168906913200210.1016/S0022-5347(05)64541-712187189LichtensteinPHolmNVVerkasaloPKIliadouAKaprioJKoskenvuoMPukkalaESkyttheAHemminkiKEnvironmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and FinlandN Engl J Med3437885200010.1056/NEJM20000713343020110891514HuangQWhitingtonTGaoPLindbergJFYangYSunJVäisänenMRSzulkinRAnnalaMYanJA prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin bindingNat Genet46126135201410.1038/ng.286224390282HazelettDJRhieSKGaddisMYanCLakelandDLCoetzeeSGEllipse/GAME-ON consortium; Practical consortiumHendersonBENoushmehrHComprehensive functional annotation of 77 prostate cancer risk lociPLoS Genet10e1004102201410.1371/journal.pgen.100410224497837EelesRAOlamaAABenllochSSaundersEJLeongamornlertDATymrakiewiczMGhoussainiMLuccariniCDennisJJugurnauth-LittleSIdentification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping arrayNat Genet4538591391e1-2201310.1038/ng.256023535732BartelDPMicroRNAs: Genomics, biogenesis, mechanism, and functionCell116281297200410.1016/S0092-8674(04)00045-514744438LimLPLauNCGarrett-EngelePGrimsonASchelterJMCastleJBartelDPLinsleyPSJohnsonJMMicroarray analysis shows that some microRNAs downregulate large numbers of target mRNAsNature433769773200510.1038/nature0331515685193HuZChenJTianTZhouXGuHXuLZengYMiaoRJinGMaHGenetic variants of miRNA sequences and non-small cell lung cancer survivalJ Clin Invest11826002608200818521189SibinMKHarshithaSMNarasingaraoKVDhananjayaIBDhavalPSChetanGKEffect of rs11614913 polymorphism on mature miR196a2 Expression and its target gene HOXC8 expression in human gliomaJ Mol Neurosci61144151201710.1007/s12031-016-0855-z27796868HashemiMDaneshHBizhaniFNarouieBSotoudehMNouralizadehASharifiaghdasFBahariGTaheriMPri-miR-34b/c rs4938723 polymorphism increased the risk of prostate cancerCancer Biomark18155159201710.3233/CBM-16005827983526HashemiMMoradiNZiaeeSANarouieBSoltaniMHRezaeiMShahkarGTaheriMAssociation between single nucleotide polymorphism in miR-499, miR-196a2, miR-146a and miR-149 and prostate cancer risk in a sample of Iranian populationJ Adv Res7491498201610.1016/j.jare.2016.03.00827222754LiuFDearKHuangLLiuLShiYNieSLiuYLuYXiangHAssociation between microRNA-27a rs895819 polymorphism and risk of colorectal cancer: A meta-analysisCancer Genet209388394201610.1016/j.cancergen.2016.08.00327751356WangCLiLYinZZhangQZhaoHTaoRWangSHuSHeYWangDAn Indel Polymorphism within pre-miR3131 confers risk for hepatocellular carcinomaCarcinogenesis38168176201728034876OmraniMHashemiMEskandari-NasabEHasaniSSMashhadiMAArbabiFTaheriMhsa-mir-499 rs3746444 gene polymorphism is associated with susceptibility to breast cancer in an Iranian populationBiomark Med8259267201410.2217/bmm.13.11824521023MullaneyJMMillsREPittardWSDevineSESmall insertions and deletions (INDELs) in human genomesHum Mol Genet19R131R136201010.1093/hmg/ddq40020858594Eskandari-NasabEHashemiMEbrahimiMAmininiaSThe functional 4-bp insertion/deletion ATTG polymorphism in the promoter region of NF-KB1 reduces the risk of BCCancer Biomark16109115201610.3233/CBM-15054626835711HashemiMShahkarGSimforooshNBasiriAZiaeeSANarouieBTaheriMAssociation of polymorphisms in PRKCI gene and risk of prostate cancer in a sample of Iranian PopulationCell Mol Biol (Noisy-le-grand)611621201526475383HashemiMHanafiBojd HEskandariNasab EBahariAHashemzehiNAShafieipourSNarouieBTaheriMGhavamiSAssociation of Adiponectin rs1501299 and rs266729 gene polymorphisms with nonalcoholic fatty liver diseaseHepat Mon13e9527201310.5812/hepatmon.952723922565LuuHNLinHYSørensenKDOgunwobiOOKumarNChornokurGPhelanCJonesDKiddLBatraJmiRNAs associated with prostate cancer risk and progressionBMC Urol1718201710.1186/s12894-017-0206-628320379WeiWLengJShaoHWangWMiR-1, a potential predictive biomarker for recurrence in prostate cancer after radical prostatectomyAm J Med Sci353315319201710.1016/j.amjms.2017.01.00628317618ValentinoAReclusaPSireraRGiallombardoMCampsCPauwelsPCrispiSRolfoCExosomal microRNAs in liquid biopsies: Future biomarkers for prostate cancerClin Transl Oncol19651657201710.1007/s12094-016-1599-528054319ShuklaKKMisraSPareekPMishraVSinghalBSharmaPRecent scenario of microRNA as diagnostic and prognostic biomarkers of prostate cancerUrol Oncol3592101201710.1016/j.urolonc.2016.10.01927890424QiuXDouYmiR-1307 promotes the proliferation of prostate cancer by targeting FOXO3ABiomed Pharmacother88430435201710.1016/j.biopha.2016.11.12028122308ChuHZhongDTangJLiJXueYTongNQinCYinCZhangZWangMA functional variant in miR-143 promoter contributes to prostate cancer riskArch Toxicol90403414201610.1007/s00204-014-1396-225354797PorkkaKPOggELSaramakiORSaramäkiORVessellaRLPukkilaHLähdesmäkiHvan WeerdenWMWolfMKallioniemiOPThe miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancersGenes Chromosomes Cancer50499509201110.1002/gcc.2087321472816ShenJParkHSXiaYMKimGSCuiSWThe polysaccharides from fermented Ganoderma lucidum mycelia induced miRNAs regulation in suppressed HepG2 cellsCarbohydr Polym103319324201410.1016/j.carbpol.2013.12.04424528735LeeYKimMHanJYeomKHLeeSBaekSHKimVNMicroRNA genes are transcribed by RNA polymerase IIEMBO J2340514060200410.1038/sj.emboj.760038515372072HashemiMBahariGNaderiMSadeghi-BojdSTaheriMPri-miR-34b/c rs4938723 polymorphism is associated with the risk of childhood acute lymphoblastic leukemiaCancer Genet209493496201610.1016/j.cancergen.2016.09.00927886674RyanBMRoblesAIHarrisCCGenetic variation in microRNA networks: The implications for cancer researchNat Rev Cancer10389402201010.1038/nrc286720495573OkuboMTaharaTShibataTYamashitaHNakamuraMYoshiokaDYonemuraJIshizukaTArisawaTHirataIAssociation between common genetic variants in pre-microRNAs and gastric cancer risk in Japanese populationHelicobacter15524531201010.1111/j.1523-5378.2010.00806.x21073609QiuFYangLZhangLYangXYangRFangWWuDChenJXieCHuangDPolymorphism in mature microRNA-608 sequence is associated with an increased risk of nasopharyngeal carcinomaGene565180186201510.1016/j.gene.2015.04.00825861865HashemiMSanaeiSRezaeiMBahariGHashemiSMMashhadiMATaheriMGhavamiSmiR-608 rs4919510 C>G polymorphism decreased the risk of breast cancer in an Iranian subpopulationExp Oncol385759201627031722
Electrophoresis pattern of the mismatch polymerase chain reaction-restriction fragment length polymorphism method for detection of a 3-bp indel polymorphism within pre-microRNA-3131. M, DNA marker; lanes 1 and 6, insertion/deletion; lanes 2 and 5, deletion/deletion; lanes 3 and 4, insertion/insertion.
Genotype and allele frequencies of a 3-bp indel (rs57408770) polymorphism of pre-microRNA-3131 in patients with PCa and controls.
Group
Polymorphism
PCa, n (%)
Controls, n (%)
Odds ratio (95% confidence interval)
P-value
Codominant
del/dela
62 (36.5)
67 (39.4)
1.00
–
del/ins
73 (42.9)
86 (50.6)
0.92 (0.58–1.46)
0.723
ins/ins
35 (20.6)
17 (10.0)
2.23 (1.13–4.37)
0.021
Dominant
del/dela
62 (36.5)
67 (39.4)
1.00
–
del/ins + ins/ins
108 (63.5)
103 (60.6)
1.3 (0.73–1.76)
0.654
Recessive
del/del + del/insa
135 (79.4)
153 (90.0)
1.00
–
ins/ins
35 (20.6)
17 (10.0)
2.33 (1.25–4.36)
0.009
Allele
dela
197 (58.0)
220 (64.7)
1.00
–
ins
143 (42.0)
120 (35.3)
1.33 (0.98–1.81)
0.083
Reference genotype/allele. PCa, prostate cancer; del, deletion; ins, insertion.
Association of 3-bp indel (rs57408770) polymorphism of pre-microRNA-3131 with clinicopathological characteristics of patients with prostate cancer.
rs3787016 C>T
Factors
del/del, n
del/ins, n
ins/ins, n
P-value
Age at diagnosis, years
0.876
≤65
43
52
26
>65
19
21
9
Stage
0.578
pT1
2
3
3
pT2a
9
9
9
pT2b
6
3
2
pT2c
26
37
14
pT3a
5
7
1
pT3b
14
14
6
Prostate specific antigen level at diagnosis, ng/ml